Amarin (AMRN) Competitors $9.81 +0.34 (+3.59%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$9.75 -0.06 (-0.62%) As of 04/15/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. EOLS, AVDL, CRON, PRAX, OCS, CDXC, NUVB, ABCL, CVAC, and XNCRShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Cronos Group (CRON), Praxis Precision Medicines (PRAX), Oculis (OCS), ChromaDex (CDXC), Nuvation Bio (NUVB), AbCellera Biologics (ABCL), CureVac (CVAC), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Evolus Avadel Pharmaceuticals Cronos Group Praxis Precision Medicines Oculis ChromaDex Nuvation Bio AbCellera Biologics CureVac Xencor Evolus (NASDAQ:EOLS) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Do insiders and institutionals have more ownership in EOLS or AMRN? 90.7% of Evolus shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 6.1% of Evolus shares are owned by insiders. Comparatively, 2.0% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, EOLS or AMRN? Evolus has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Amarin has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Does the media favor EOLS or AMRN? In the previous week, Evolus had 8 more articles in the media than Amarin. MarketBeat recorded 17 mentions for Evolus and 9 mentions for Amarin. Evolus' average media sentiment score of 0.27 beat Amarin's score of 0.21 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend EOLS or AMRN? Evolus currently has a consensus target price of $24.67, indicating a potential upside of 144.47%. Given Evolus' higher possible upside, research analysts plainly believe Evolus is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Amarin 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, EOLS or AMRN? Amarin has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M2.41-$61.69M-$0.81-12.46Amarin$228.61M0.88-$59.11M-$4.00-2.45 Is EOLS or AMRN more profitable? Amarin has a net margin of -16.33% compared to Evolus' net margin of -22.33%. Amarin's return on equity of -7.22% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.33% -847.60% -22.15% Amarin -16.33%-7.22%-4.96% Does the MarketBeat Community favor EOLS or AMRN? Amarin received 483 more outperform votes than Evolus when rated by MarketBeat users. Likewise, 73.39% of users gave Amarin an outperform vote while only 73.08% of users gave Evolus an outperform vote. CompanyUnderperformOutperformEvolusOutperform Votes36173.08% Underperform Votes13326.92% AmarinOutperform Votes84473.39% Underperform Votes30626.61% SummaryEvolus beats Amarin on 10 of the 17 factors compared between the two stocks. Remove Ads Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.03M$6.32B$5.33B$7.55BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-108.786.7921.8017.80Price / Sales0.88221.52377.9393.21Price / CashN/A65.6738.1534.64Price / Book7.255.806.433.99Net Income-$59.11M$141.86M$3.20B$247.23M7 Day Performance13.89%8.91%6.37%7.11%1 Month Performance18.29%-12.65%-8.70%-6.38%1 Year Performance-46.71%-12.38%10.26%-0.29% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.2168 of 5 stars$9.81+3.6%N/A-46.6%$201.44M$228.61M-109.00360High Trading VolumeEOLSEvolus3.4956 of 5 stars$10.24-4.2%$24.67+140.9%-14.0%$651.13M$266.27M-11.25170Analyst RevisionPositive NewsGap DownAVDLAvadel Pharmaceuticals2.2544 of 5 stars$6.69-1.6%$19.88+197.1%N/A$646.45M$169.12M-8.4770Analyst RevisionNews CoverageGap DownCRONCronos Group1.5759 of 5 stars$1.68-1.8%$3.00+78.6%-29.5%$642.65M$117.62M-12.92450PRAXPraxis Precision Medicines2.9287 of 5 stars$31.53-3.4%$123.33+291.2%-44.4%$635.74M$8.55M-3.06110OCSOculis1.9829 of 5 stars$14.37-7.3%$29.50+105.3%+49.0%$627.42M$980,000.00-7.452News CoverageHigh Trading VolumeCDXCChromaDex2.2758 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Analyst ForecastNUVBNuvation Bio2.4714 of 5 stars$1.81+8.7%$8.75+384.8%-29.7%$611.32M$7.87M-0.8360News CoverageGap DownHigh Trading VolumeABCLAbCellera Biologics2.1342 of 5 stars$2.05-1.9%$7.00+241.5%-41.9%$610.88M$28.83M-3.36500Gap DownHigh Trading VolumeCVACCureVac3.3305 of 5 stars$2.65+2.3%$10.00+277.4%+21.9%$593.28M$543.28M4.82880Earnings ReportUpcoming EarningsShort Interest ↑XNCRXencor3.3698 of 5 stars$8.37-3.7%$34.38+310.7%-52.6%$589.77M$110.49M-2.62280Gap Down Remove Ads Related Companies and Tools Related Companies Evolus Alternatives Avadel Pharmaceuticals Alternatives Cronos Group Alternatives Praxis Precision Medicines Alternatives Oculis Alternatives ChromaDex Alternatives Nuvation Bio Alternatives AbCellera Biologics Alternatives CureVac Alternatives Xencor Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMRN Stock Free AMRN Stock Alerts